Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1968-1974

  Henry, Karl W ^a   Cruz, M Cristina ^a,b   Katiyar, Santosh K ^a   Edlind, Thomas D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; AZITHROMYCIN; CIPROFLOXACIN; DOXYCYCLINE; FLUCONAZOLE; FLUOROURACIL; FLUPHENAZINE; FOSCARNET; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LINCOMYCIN; PYRAZINAMIDE; PYRIMETHAMINE; RIFAMPICIN; RNA; SULFADIAZINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZIDOVUDINE;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; GENE OVEREXPRESSION; IMMUNE DEFICIENCY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0032856116     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1968     Document Type: Article

References (45)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1997. Short protocols in molecular biology, 3rd ed., p. 4-22-4-25. John Wiley & Sons, Inc., New York, N.Y.
2. Barchiesi, F., A. L. Colombo, D. A. McGough, A. W. Fothergill, and M. G. Rinaldi. 1994. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1530-1533.
3. Blaser, J., B. Joos, M. Opravil, and R. Luthy. 1993. Variability of serum concentration of trimethoprim and sulfamethoxazole during high dose therapy. Infection 21:206-209.
4. Boken, D., S. Swindells, and M. Rinaldi. 1993. Fluconazole resistant Candida albicans. Clin. Infect. Dis. 17:1018-1021.
5. Delahodde, A., T. Delaveau, and C. Jacq. 1995. Positive autoregulation of the yeast transcription factor Pdr3p, which is involved in control of drug resistance. Mol. Cell. Biol. 15:4043-4051.
6. Edlind, T. D., K. W. Henry, and S. K. Katiyar. 1998. Genetics of MDR-mediated azole resistance in Saccharomyces cerevisiae, abstr. C-154, p. 113. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Fernandes, L., C. Rodrigues-Pousada, and K. Struhl. 1997. Yap, a novel family of eight bZIP proteins in Saccharomyces cerevisiae with distinct biological functions. Mol. Cell. Biol. 17:6982-6993.
8. Fling, M. E., A. T. Kopf, J. A. Dorman, H. A. Smith, and Y. Koltin. 1991. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet. 227:318-329.
9. Harvey, R. P., R. A. Isenberg, and D. A. Stevens. 1980. Molecular modifications of imidazole compounds: studies of activity and synergy in vitro and of pharmacology and therapy of Blastomycosis in a mouse model. Rev. Infect. Dis. 2:559-569.
10. Henry, K. W., and T. D. Edlind. 1998. Induction of multidrug resistance genes in Candida albicans by antimicrobial agents leads to antagonism of azole activity, abstr. J-89, p. 476. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Hernaez, M. L., C. Gil, J. Pla, and C. Nombela. 1998. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 14:517-526.
12. Hirata, D., K. Yano, K. Miyahara, and T. Miyakawa. 1994. Saccharomyces cerevisiae YDRI, which encodes a member of the ATP-binding cassette (ABC) superfamily, is required for multidrug resistance. Curr. Genet. 26: 285-294.
13. Johnson, E. M., M. D. Richardson, and D. W. Warnock. 1984. In vitro resistance to imidazole antifungals in Candida albicans. J. Antimicrob. Chemother. 13:547-558.
14. Kanazawa, S., M. Driscoll, and K. Struhl. 1988. ATRI. A Saccharomyces cerevisiae gene encoding a transmembrane protein required for aminotriazole resistance. Mol. Cell. Biol. 8:664-673.
15. Karcioglu, Z. A., A. El-Yazigi, M. H. Jabak, A. H. Choudhury, and W. S. Ahmed. 1998. Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels. Ophthalmology 195:658-661.
16. Karlsson, M., S. Hammers, I. Nilsson-Ehle, A. S. Malmborg, and B. Wretlind. 1996. Concentration of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob. Agents Chemother. 40:1104-1107.
17. Katiyar, S. K., and T. D. Edlind. 1998. Identification of Candida krusei multidrug resistance genes: potential role in azole resistance, abstr. C-153, p. 113. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Krishnamurthy, S., V. Gupta, R. Prasad, S. L. Panwar, and R. Prasad. 1998. Expression of CDR1, a multidrug resistance gene of Candida albicans-transcriptional activation by heat shock, drugs, and steroid hormones. FEMS Microbiol. Lett. 160:191-197.
19. Lortholary, O., and B. Dupont. 1997. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin. Microbiol. Rev. 10:477-504.
20. Losberger, C., and J. F. Ernst. 1989. Sequence of the Candida albicans gene encoding actin. Nucleic Acids Res. 17:9488.
21. Mahajan, M., D. Rohatgi, V. Talwar, S. K. Patni, P. Majahan, and D. S. Agarwal. 1997. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J. Commun. Dis. 29:269-274.
22. Marcus, S., G. Ziv, A. Glickman, D. Ozbonfil, B. Bartoov, and A. Klein. 1994. Lincomycin and spectinomycin in the treatment of breeding rams with semen contaminated with ureaplasmas. Res. Vet. Sci. 57:393-394.
23. McGinnis, M. R., and M. G. Rinaldi. 1986. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids, p. 260. In V. Lorain (ed.). Antibiotics in laboratory medicine, 2nd ed. Williams and Wilkins Co., Baltimore, Md.
24. Moskopp, D., and E. Lotterer. 1993. Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst. Neurosurg. Rev. 16:35-37.
25. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Ng, T. T., and D. W. Denning. 1993. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J. Infect. 26L:117-125.
27. Opravil, M., B. Joos, and R. Lüthy. 1994. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob. Agents Chemother. 38:1197-1199.
28. Petersen, D., S. Demertziz, M. Freund, and G. Schumann. 1994. Individualization of 5-fluorocytosine therapy. Chemotherapy 40:149-156.
29. Pfaller, M. 1994. Epidemiology and control of fungal infections. Clin. Infect. Dis. 19(Suppl. 1):S8-S13.
30. Pohlenz-Zertuche, H. O., M. P. Brown, R. Gronwall, G. A. Kunkle, and K. Merrit. 1992. Serum and skin concentrations after multiple-dose oral administration of trimethoprim-sulfadiazine in dogs. Am. J. Vet. Res. 53:1273-1276.
31. Prasad, R., P. DeWergifosse, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
32. Rubio, T. T., M. V. Miles, J. T. Lettieri, R. J. Kuhn, R. M. Echols, and D. A. Church. 1997. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr. Infect. Dis. J. 16:112-117.
33. Sahal, J., K. Gallicano, E. Ormsby, G. Garber, and D. W. Cameron. 1994. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 8:793-796.
34. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405-416.
35. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
36. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
37. Schmitt, M., T. A. Brown, and B. L. Trumpower. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092.
38. Seelig, A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251:252-261.
39. Seidel, E. A., S. Koenig, and M. A. Polis. 1993. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. AIDS 7:941-945.
40. Seth, V., S. D. Seth, A. Beotra, O. P. Semwal, V. D'monty, and S. Mukhopadhya. 1994. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen. Indian Pediatr. 31: 279-285.
41. Siau, H., and D. Kerridge. 1998. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J. Antimicrob. Chemother. 41:357-366.
42. Singhal, K. C., and M. K. Varshney. 1991. Effect of simultaneous isoniazid administration on pharmacokinetics parameters of pyrazinamide. J. Indian Med. Assoc. 89:227-229.
43. Walsh, T. J., P. Whitcomb, S. Piscitelli, W. D. Figg, S. Hill, S. J. Chanock, P. Jarosinski, R. Gupta, and P. A. Pizza. 1997. Safety, tolerance, and pharmacokinetics of ampholericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41:1944-1948.
44. White, T. C., R. A. Bowden, and K. A. Marr. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
45. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.